Dr. Feng Lin, Director of Research at Bio-Matrix Scientific Group Inc. (OTCBulletinBoard: BMSN) and Entest BioMedical Inc., today stated that he believes that an effective new therapy for “traumatic brain injury” (TBI) using autologous “adipose-derived” stem cells represents a potential cure for TBI. According to Dr. Lin, both Bio-Matrix and Entest BioMedical are now studying the “therapeutic effect of fat stem cells on traumatic brain injury-associated brain ischemia and inflammation and replacement of damaged neurons with neuron cells differentiated from fat cells.” Bio-Matrix Scientific Group Inc. and Entest BioMedical Inc. recently submitted a research summary proposal to the U.S. Army with a goal of funding traumatic brain injury treatment research. BMSN is a San Diego-based biotechnology research and development company. Entest BioMedical Inc. is a wholly-owned subsidiary of BMSN. Entest is focusing on stem cell research applications, as well as testing procedures for diabetes.
“Currently there is no effective therapeutic approach to reverse the initial brain damage caused by trauma,” stated Dr. Lin. “Brain cells or neurons have limited ability for self-repair and spontaneous axonal regeneration. Extensive studies have been focusing on novel therapeutic strategies for traumatic brain injury. In my opinion, adipose-derived stem cells could possess the capacity for self-renewal and differentiation into diverse cell types such as neural cells. We could be looking at an exciting and potential cure for traumatic brain injury patients.”
Traumatic brain injury (TBI) occurs when an external force injures the brain. TBI is a major cause of disability and death worldwide, but especially in young people. Causes include vehicle accidents, falls, violence, as well as explosive blasts in battle fields. In the U.S., approximately 1.5 million new TBI cases occur each year, adding to the almost 6.5 million cases that are permanently affected by the irreversible physical, cognitive, and psychological defects associated with TBI. The total annual economic impact of TBI is approximately $60 billion.